CSF T-TAU/Aβ 42 predicts white matter microstructure in healthy adults at risk for alzheimer's disease

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Bendlin, Barbara B ^a,b   Carlsson, Cynthia M ^a,b   Johnson, Sterling C ^a,b   Zetterberg, Henrik ^c   Blennow, Kaj ^c   Willette, Auriel A ^a,b   Okonkwo, Ozioma C ^a,b   Sodhi, Aparna ^a,b   Ries, Michele L ^a,b   Birdsill, Alex C ^a,b   Alexander, Andrew L ^b,d   Rowley, Howard A ^b   Puglielli, Luigi ^a,b   Asthana, Sanjay ^a,b   Sager, Mark A ^a,b  

^a WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); MAPT PROTEIN, HUMAN; PEPTIDE FRAGMENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; FAMILY HISTORY; FEMALE; GRAY MATTER; HUMAN; MALE; NEUROFILAMENT; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN PHOSPHORYLATION; RECOGNITION; WHITE MATTER; ANALYSIS OF VARIANCE; CEREBROSPINAL FLUID; GENETICS; METABOLISM; MIDDLE AGED; MYELIN SHEATH; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; UNITED STATES;

ADULT; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; DIFFUSION TENSOR IMAGING; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYELIN SHEATH; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; PHOSPHORYLATION; RECOGNITION (PSYCHOLOGY); TAU PROTEINS; WISCONSIN;

EID: 84862027790     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037720     Document Type: Article

References (123)

1. De Meyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, et al. (2010) Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 67: 949-956.
2. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, et al. (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65: 403-413.
3. Galasko D, Chang L, Motter R, Clark CM, Kaye J, et al. (1998) High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 55: 937-945.
4. Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, et al. (2003) Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. Jama 289: 2094-2103.
5. Smach MA, Charfeddine B, Ben Othman L, Lammouchi T, Dridi H, et al. (2009) Evaluation of cerebrospinal fluid tau/beta-amyloid(42) ratio as diagnostic markers for Alzheimer disease. Eur Neurol 62: 349-355.
6. Davatzikos C, Bhatt P, Shaw LM, Batmanghelich KN, Trojanowski JQ, (2011) Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification. Neurobiol Aging.
7. Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, et al. (2004) Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry 9: 705-710.
8. Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, et al. (2007) Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord 23: 316-320.
9. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, et al. (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. Jama 302: 385-393.
10. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, et al. (2007) Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64: 343-349.
11. Glodzik L, de Santi S, Tsui WH, Mosconi L, Zinkowski R, et al. (2011) Phosphorylated tau 231, memory decline and medial temporal atrophy in normal elders. Neurobiol Aging.
12. Desikan RS, Sabuncu MR, Schmansky NJ, Reuter M, Cabral HJ, et al. (2010) Selective disruption of the cerebral neocortex in Alzheimer's disease. PLoS One 5: e12853.
13. Fjell AM, Walhovd KB, Fennema-Notestine C, McEvoy LK, Hagler DJ, et al. (2010) Brain atrophy in healthy aging is related to CSF levels of Abeta1-42. Cereb Cortex 20: 2069-2079.
14. Schott JM, Bartlett JW, Fox NC, Barnes J, (2010) Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Abeta1-42. Ann Neurol 68: 825-834.
15. Ott BR, Cohen RA, Gongvatana A, Okonkwo OC, Johanson CE, et al. (2010) Brain ventricular volume and cerebrospinal fluid biomarkers of Alzheimer's disease. J Alzheimers Dis 20: 647-657.
16. Fagan AM, Head D, Shah AR, Marcus D, Mintun M, et al. (2009) Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol 65: 176-183.
17. Basser PJ, Pierpaoli C, (1996) Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. J Magn Reson B 111: 209-219.
18. Hofling AA, Kim JH, Fantz CR, Sands MS, Song SK, (2009) Diffusion tensor imaging detects axonal injury and demyelination in the spinal cord and cranial nerves of a murine model of globoid cell leukodystrophy. NMR Biomed.
19. Feng S, Hong Y, Zhou Z, Jinsong Z, Xiaofeng D, et al. (2009) Monitoring of acute axonal injury in the swine spinal cord with EAE by diffusion tensor imaging. J Magn Reson Imaging 30: 277-285.
20. Mac Donald CL, Dikranian K, Bayly P, Holtzman D, Brody D, (2007) Diffusion tensor imaging reliably detects experimental traumatic axonal injury and indicates approximate time of injury. J Neurosci 27: 11869-11876.
21. Sun SW, Liang HF, Trinkaus K, Cross AH, Armstrong RC, et al. (2006) Noninvasive detection of cuprizone induced axonal damage and demyelination in the mouse corpus callosum. Magn Reson Med 55: 302-308.
22. Song SK, Yoshino J, Le TQ, Lin SJ, Sun SW, et al. (2005) Demyelination increases radial diffusivity in corpus callosum of mouse brain. Neuroimage 26: 132-140.
23. Song SK, Sun SW, Ramsbottom MJ, Chang C, Russell J, et al. (2002) Dysmyelination revealed through MRI as increased radial (but unchanged axial) diffusion of water. Neuroimage 17: 1429-1436.
24. Harsan LA, Poulet P, Guignard B, Steibel J, Parizel N, et al. (2006) Brain dysmyelination and recovery assessment by noninvasive in vivo diffusion tensor magnetic resonance imaging. J Neurosci Res 83: 392-402.
25. Budde MD, Kim JH, Liang HF, Russell JH, Cross AH, et al. (2007) Axonal injury detected by in vivo diffusion tensor imaging correlates with neurological disability in a mouse model of multiple sclerosis. NMR Biomed.
26. Wu Q, Butzkueven H, Gresle M, Kirchhoff F, Friedhuber A, et al. (2007) MR diffusion changes correlate with ultra-structurally defined axonal degeneration in murine optic nerve. Neuroimage 37: 1138-1147.
27. Bozzali M, Falini A, Franceschi M, Cercignani M, Zuffi M, et al. (2002) White matter damage in Alzheimer's disease assessed in vivo using diffusion tensor magnetic resonance imaging. J Neurol Neurosurg Psychiatry 72: 742-746.
28. Fellgiebel A, Schermuly I, Gerhard A, Keller I, Albrecht J, et al. (2008) Functional relevant loss of long association fibre tracts integrity in early Alzheimer's disease. Neuropsychologia 46: 1698-1706.
29. Hanyu H, Asano T, Sakurai H, Imon Y, Iwamoto T, et al. (1999) Diffusion-weighted and magnetization transfer imaging of the corpus callosum in Alzheimer's disease. J Neurol Sci 167: 37-44.
30. Huang J, Friedland RP, Auchus AP, (2007) Diffusion tensor imaging of normal-appearing white matter in mild cognitive impairment and early Alzheimer disease: preliminary evidence of axonal degeneration in the temporal lobe. AJNR Am J Neuroradiol 28: 1943-1948.
31. Rose SE, Janke AL, Chalk JB, (2008) Gray and white matter changes in Alzheimer's disease: a diffusion tensor imaging study. J Magn Reson Imaging 27: 20-26.
32. Salat DH, Tuch DS, van der Kouwe AJ, Greve DN, Pappu V, et al. (2008) White matter pathology isolates the hippocampal formation in Alzheimer's disease. Neurobiol Aging.
33. Stahl R, Dietrich O, Teipel SJ, Hampel H, Reiser MF, et al. (2007) White matter damage in Alzheimer disease and mild cognitive impairment: assessment with diffusion-tensor MR imaging and parallel imaging techniques. Radiology 243: 483-492.
34. Takahashi S, Yonezawa H, Takahashi J, Kudo M, Inoue T, et al. (2002) Selective reduction of diffusion anisotropy in white matter of Alzheimer disease brains measured by 3.0 Tesla magnetic resonance imaging. Neurosci Lett 332: 45-48.
35. Xie S, Xiao JX, Gong GL, Zang YF, Wang YH, et al. (2006) Voxel-based detection of white matter abnormalities in mild Alzheimer disease. Neurology 66: 1845-1849.
36. Duan JH, Wang HQ, Xu J, Lin X, Chen SQ, et al. (2006) White matter damage of patients with Alzheimer's disease correlated with the decreased cognitive function. Surg Radiol Anat 28: 150-156.
37. Medina D, deToledo-Morrell L, Urresta F, Gabrieli JDE, Moseley M, et al. (2006) White matter changes in mild cognitive impairment and AD: A diffusion tensor imaging study. Neurobiology of Aging 27: 663-672.
38. Canu E, McLaren DG, Fitzgerald ME, Bendlin BB, Zoccatelli G, et al. (2009) Microstructural Diffusion Changes are Independent of Macrostructural Volume Loss in Moderate to Severe Alzheimer's Disease. J Alzheimers Dis.
39. Stricker NH, Schweinsburg BC, Delano-Wood L, Wierenga CE, Bangen KJ, et al. (2009) Decreased white matter integrity in late-myelinating fiber pathways in Alzheimer's disease supports retrogenesis. Neuroimage 45: 10-16.
40. Cho H, Yang DW, Shon YM, Kim BS, Kim YI, et al. (2008) Abnormal integrity of corticocortical tracts in mild cognitive impairment: a diffusion tensor imaging study. J Korean Med Sci 23: 477-483.
41. Fellgiebel A, Wille P, Muller MJ, Winterer G, Scheurich A, et al. (2004) Ultrastructural hippocampal and white matter alterations in mild cognitive impairment: a diffusion tensor imaging study. Dement Geriatr Cogn Disord 18: 101-108.
42. Kantarci K, Jack CR Jr, Xu YC, Campeau NG, O'Brien PC, et al. (2001) Mild cognitive impairment and Alzheimer disease: regional diffusivity of water. Radiology 219: 101-107.
43. Lovblad KO, Delavelle J, Wetzel S, Kelekis AD, Assal F, et al. (2004) ADC mapping of the aging frontal lobes in mild cognitive impairment. Neuroradiology 46: 282-286.
44. Rose SE, McMahon KL, Janke AL, O'Dowd B, de Zubicaray G, et al. (2006) Diffusion indices on magnetic resonance imaging and neuropsychological performance in amnestic mild cognitive impairment. J Neurol Neurosurg Psychiatry 77: 1122-1128.
45. Fellgiebel A, Muller MJ, Wille P, Dellani PR, Scheurich A, et al. (2005) Color-coded diffusion-tensor-imaging of posterior cingulate fiber tracts in mild cognitive impairment. Neurobiol Aging 26: 1193-1198.
46. Stenset V, Bjornerud A, Fjell AM, Walhovd KB, Hofoss D, et al. (2009) Cingulum fiber diffusivity and CSF T-tau in patients with subjective and mild cognitive impairment. Neurobiol Aging.
47. Nierenberg J, Pomara N, Hoptman MJ, Sidtis JJ, Ardekani BA, et al. (2005) Abnormal white matter integrity in healthy apolipoprotein E epsilon4 carriers. Neuroreport 16: 1369-1372.
48. Persson J, Lind J, Larsson A, Ingvar M, Cruts M, et al. (2006) Altered brain white matter integrity in healthy carriers of the APOE epsilon4 allele: a risk for AD? Neurology 66: 1029-1033.
49. Ryan L, Walther K, Bendlin BB, Lue LF, Walker DG, et al. (2011) Age-related differences in white matter integrity and cognitive function are related to APOE status. Neuroimage 54: 1565-1577.
50. Bendlin BB, Ries ML, Canu E, Sodhi A, Lazar M, et al. (2010) White matter is altered with parental family history of Alzheimer's disease. Alzheimers Dement 6: 394-403.
51. Xiong C, Roe CM, Buckles V, Fagan A, Holtzman D, et al. (2011) Role of Family History for Alzheimer Biomarker Abnormalities in the Adult Children Study. Arch Neurol 68: 1313-1319.
52. Smith CD, Chebrolu H, Andersen AH, Powell DA, Lovell MA, et al. (2010) White matter diffusion alterations in normal women at risk of Alzheimer's disease. Neurobiol Aging 31: 1122-1131.
53. Sager MA, Hermann B, La Rue A, (2005) Middle-aged children of persons with Alzheimer's disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer's Prevention. J Geriatr Psychiatry Neurol 18: 245-249.
54. Olsson B, Zetterberg H, Hampel H, Blennow K, (2011) Biomarker-based dissection of neurodegenerative diseases. Prog Neurobiol.
55. Ashburner J, Friston KJ, (2000) Voxel-based morphometry-the methods. Neuroimage 11: 805-821.
56. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, et al. (1989) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 39: 1159-1165.
57. McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA workgroup under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34: 939-944.
58. Folstein MF, Folstein SE, McHugh PR, (1975) "Mini Mental State": a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatry Research 12: 189-198.
59. Benedict R, (1997) Brief Visuospatial Memory Test-Revised. Lutz, FL Psychological Assessment Resources Inc.
60. Benton AL, Hamsher K, Sivan AB, (1983) Multilingual Aphasia Examination. Iowa City AJA Associates.
61. Reitan RM, Wolfson D, (1993) The Halstead-Reitan Neuropsychological Test Battery: Theory and clinical interpretation. Tucson Neuropsychology Press.
62. Wechsler D, (1997) Wechsler Adult Intelligence Scale-Third Edition. New York Psych Corp.
63. Rey A, (1964) L'examen clinique en psychologie. Paris Presses Universitaires de France.
64. Carlsson CM, Gleason CE, Johnson SC, Xu G, Huang Y, et al. (2010) A randomized, double-blind placebo-controlled trial of simvastatin on CSF, MRI, and cognitive biomarkers in middle-aged adults at risk for Alzheimer's disease: The ESPRIT Study. Alzheimer's and Dementia 6: S151-S152.
65. Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, et al. (2005) Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 51: 336-345.
66. Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C, (1996) Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 67: 2013-2018.
67. Ashburner J, Friston KJ, (2005) Unified segmentation. Neuroimage 26: 839-851.
68. Bendlin BB, Fitzgerald ME, Ries ML, Xu G, Kastman EK, et al. (2010) White matter in aging and cognition: a cross-sectional study of microstructure in adults aged eighteen to eighty-three. Dev Neuropsychol 35: 257-277.
69. Pfefferbaum A, Sullivan EV, Hedehus M, Lim KO, Adalsteinsson E, et al. (2000) Age-related decline in brain white matter anisotropy measured with spatially corrected echo-planar diffusion tensor imaging. Magn Reson Med 44: 259-268.
70. Salat DH, Tuch DS, Greve DN, van der Kouwe AJ, Hevelone ND, et al. (2005) Age-related alterations in white matter microstructure measured by diffusion tensor imaging. Neurobiol Aging 26: 1215-1227.
71. Menzler K, Belke M, Wehrmann E, Krakow K, Lengler U, et al. (2011) Men and women are different: diffusion tensor imaging reveals sexual dimorphism in the microstructure of the thalamus, corpus callosum and cingulum. Neuroimage 54: 2557-2562.
72. Genovese CR, Lazar NA, Nichols T, (2002) Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage 15: 870-878.
73. Bartzokis G, Lu PH, Geschwind DH, Tingus K, Huang D, et al. (2007) Apolipoprotein E affects both myelin breakdown and cognition: implications for age-related trajectories of decline into dementia. Biol Psychiatry 62: 1380-1387.
74. Desai MK, Guercio BJ, Narrow WC, Bowers WJ, (2011) An Alzheimer's disease-relevant presenilin-1 mutation augments amyloid-beta-induced oligodendrocyte dysfunction. Glia 59: 627-640.
75. Desai MK, Sudol KL, Janelsins MC, Mastrangelo MA, Frazer ME, et al. (2009) Triple-transgenic Alzheimer's disease mice exhibit region-specific abnormalities in brain myelination patterns prior to appearance of amyloid and tau pathology. Glia 57: 54-65.
76. Herukka SK, Pennanen C, Soininen H, Pirttila T, (2008) CSF Abeta42, tau and phosphorylated tau correlate with medial temporal lobe atrophy. J Alzheimers Dis 14: 51-57.
77. Sole-Padulles C, Llado A, Bartres-Faz D, Fortea J, Sanchez-Valle R, et al. (2011) Association between cerebrospinal fluid tau and brain atrophy is not related to clinical severity in the Alzheimer's disease continuum. Psychiatry Res 192: 140-146.
78. de la Monte SM, (1989) Quantitation of cerebral atrophy in preclinical and end-stage Alzheimer's disease. Ann Neurol 25: 450-459.
79. Scheltens P, Barkhof F, Leys D, Wolters EC, Ravid R, et al. (1995) Histopathologic correlates of white matter changes on MRI in Alzheimer's disease and normal aging. Neurology 45: 883-888.
80. Bronge L, Bogdanovic N, Wahlund LO, (2002) Postmortem MRI and histopathology of white matter changes in Alzheimer brains. A quantitative, comparative study. Dement Geriatr Cogn Disord 13: 205-212.
81. Roher AE, Weiss N, Kokjohn TA, Kuo YM, Kalback W, et al. (2002) Increased A beta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease. Biochemistry 41: 11080-11090.
82. Li S, Pu F, Shi F, Xie S, Wang Y, et al. (2008) Regional white matter decreases in Alzheimer's disease using optimized voxel-based morphometry. Acta Radiol 49: 84-90.
83. Stout JC, Jernigan TL, Archibald SL, Salmon DP, (1996) Association of dementia severity with cortical gray matter and abnormal white matter volumes in dementia of the Alzheimer type. Arch Neurol 53: 742-749.
84. Salat DH, Greve DN, Pacheco JL, Quinn BT, Helmer KG, et al. (2009) Regional white matter volume differences in nondemented aging and Alzheimer's disease. Neuroimage 44: 1247-1258.
85. Im K, Lee JM, Won Seo S, Hyung Kim S, Kim SI, et al. (2008) Sulcal morphology changes and their relationship with cortical thickness and gyral white matter volume in mild cognitive impairment and Alzheimer's disease. Neuroimage 43: 103-113.
86. Balthazar ML, Yasuda CL, Pereira FR, Pedro T, Damasceno BP, et al. (2009) Differences in grey and white matter atrophy in amnestic mild cognitive impairment and mild Alzheimer's disease. Eur J Neurol 16: 468-474.
87. Chaim TM, Duran FL, Uchida RR, Perico CA, de Castro CC, et al. (2007) Volumetric reduction of the corpus callosum in Alzheimer's disease in vivo as assessed with voxel-based morphometry. Psychiatry Res 154: 59-68.
88. Baxter LC, Sparks DL, Johnson SC, Lenoski B, Lopez JE, et al. (2006) Relationship of cognitive measures and gray and white matter in Alzheimer's disease. J Alzheimers Dis 9: 253-260.
89. Teipel SJ, Hampel H, Alexander GE, Schapiro MB, Horwitz B, et al. (1998) Dissociation between corpus callosum atrophy and white matter pathology in Alzheimer's disease. Neurology 51: 1381-1385.
90. Teipel SJ, Bayer W, Alexander GE, Zebuhr Y, Teichberg D, et al. (2002) Progression of corpus callosum atrophy in Alzheimer disease. Arch Neurol 59: 243-248.
91. Vermersch P, Scheltens P, Barkhof F, Steinling M, Leys D, (1994) Evidence for atrophy of the corpus callosum in Alzheimer's disease. Eur Neurol 34: 83-86.
92. Wang PJ, Saykin AJ, Flashman LA, Wishart HA, Rabin LA, et al. (2006) Regionally specific atrophy of the corpus callosum in AD, MCI and cognitive complaints. Neurobiol Aging 27: 1613-1617.
93. Mielke MM, Kozauer NA, Chan KC, George M, Toroney J, et al. (2009) Regionally-specific diffusion tensor imaging in mild cognitive impairment and Alzheimer's disease. Neuroimage 46: 47-55.
94. Terry RD, (1998) The cytoskeleton in Alzheimer disease. J Neural Transm (Suppl 53): 141-145.
95. Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, et al. (2005) Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 307: 1282-1288.
96. Bartzokis G, Sultzer D, Lu PH, Nuechterlein KH, Mintz J, et al. (2004) Heterogeneous age-related breakdown of white matter structural integrity: implications for cortical "disconnection" in aging and Alzheimer's disease. Neurobiol Aging 25: 843-851.
97. Bartzokis G, Lu PH, Tishler TA, Fong SM, Oluwadara B, et al. (2007) Myelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications. Neurochem Res 32: 1655-1664.
98. Bartzokis G, (2004) Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease. Neurobiol Aging 25: 5-18; author reply 49-62.
99. Friede RL, Samorajski T, (1970) Axon caliber related to neurofilaments and microtubules in sciatic nerve fibers of rats and mice. Anat Rec 167: 379-387.
100. Sjogren M, Blomberg M, Jonsson M, Wahlund LO, Edman A, et al. (2001) Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J Neurosci Res 66: 510-516.
101. Norgren N, Rosengren L, Stigbrand T, (2003) Elevated neurofilament levels in neurological diseases. Brain Res 987: 25-31.
102. Hu YY, He SS, Wang XC, Duan QH, Khatoon S, et al. (2002) Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients. Neurosci Lett 320: 156-160.
103. Rosengren LE, Karlsson JE, Sjogren M, Blennow K, Wallin A, (1999) Neurofilament protein levels in CSF are increased in dementia. Neurology 52: 1090-1093.
104. Andreasen N, Gottfries J, Vanmechelen E, Vanderstichele H, Davidson P, et al. (2001) Evaluation of CSF biomarkers for axonal and neuronal degeneration, gliosis, and beta-amyloid metabolism in Alzheimer's disease. J Neurol Neurosurg Psychiatry 71: 557-558.
105. Vandermeeren M, Mercken M, Vanmechelen E, Six J, van de Voorde A, et al. (1993) Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 61: 1828-1834.
106. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, et al. (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59: 512-519.
107. Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, et al. (2009) Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66: 382-389.
108. Richter-Landsberg C, (2008) The cytoskeleton in oligodendrocytes. Microtubule dynamics in health and disease. J Mol Neurosci 35: 55-63.
109. Iwatsubo T, Hasegawa M, Ihara Y, (1994) Neuronal and glial tau-positive inclusions in diverse neurologic diseases share common phosphorylation characteristics. Acta Neuropathol 88: 129-136.
110. Umahara T, Tsuchiya K, Ikeda K, Kanaya K, Iwamoto T, et al. (2002) Demonstration and distribution of tau-positive glial coiled body-like structures in white matter and white matter threads in early onset Alzheimer's disease. Neuropathology 22: 9-12.
111. Nishimura M, Tomimoto H, Suenaga T, Namba Y, Ikeda K, et al. (1995) Immunocytochemical characterization of glial fibrillary tangles in Alzheimer's disease brain. Am J Pathol 146: 1052-1058.
112. Gotz J, Chen F, Barmettler R, Nitsch RM, (2001) Tau filament formation in transgenic mice expressing P301L tau. J Biol Chem 276: 529-534.
113. Higuchi M, Ishihara T, Zhang B, Hong M, Andreadis A, et al. (2002) Transgenic mouse model of tauopathies with glial pathology and nervous system degeneration. Neuron 35: 433-446.
114. Lin WL, Lewis J, Yen SH, Hutton M, Dickson DW, (2003) Filamentous tau in oligodendrocytes and astrocytes of transgenic mice expressing the human tau isoform with the P301L mutation. Am J Pathol 162: 213-218.
115. Buerger K, Alafuzoff I, Ewers M, Pirttila T, Zinkowski R, et al. (2007) No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 130: e82.
116. Braak H, Braak E, (1997) Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 18: 351-357.
117. Kester MI, Blankenstein MA, Bouwman FH, van Elk EJ, Scheltens P, et al. (2009) CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age. J Alzheimers Dis 16: 601-607.
118. Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, et al. (2004) Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. Biol Psychiatry 56: 670-676.
119. Carlsson CM, Gleason CE, Hess TM, Moreland KA, Blazel HM, et al. (2008) Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer's disease. J Alzheimers Dis 13: 187-197.
120. Andersson C, Blennow K, Johansson SE, Almkvist O, Engfeldt P, et al. (2007) Differential CSF biomarker levels in APOE-epsilon4-positive and-negative patients with memory impairment. Dement Geriatr Cogn Disord 23: 87-95.
121. Herukka SK, Hallikainen M, Soininen H, Pirttila T, (2005) CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 64: 1294-1297.
122. Stomrud E, Hansson O, Zetterberg H, Blennow K, Minthon L, et al. (2010) Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. Arch Neurol 67: 217-223.
123. Tournier JD, Mori S, Leemans A, (2011) Diffusion tensor imaging and beyond. Magn Reson Med 65: 1532-1556.